Nectar Lifesciences Completes Business Transformation, Reports Nil Revenue and Increased Loss

For the financial year ended March 31, 2026, Nectar Lifesciences reported a net loss after tax of INR 2,928.91 million, a significant increase from INR 1,136.81 million in the previous year. The company's revenue from operations was Nil, primarily due to the divestment of its core pharmaceutical (API and Formulation) and menthol businesses.

Reader Takeaway: Strategic shift to real estate; higher net loss and nil revenue pose immediate concerns.

What just happened

Nectar Lifesciences has undergone a major business transformation, selling its core pharmaceutical and menthol businesses to Ceph Lifesciences Private Limited via a slump sale in November 2025. The company is also in the process of selling its Empty Hard Gelatin Capsule (EHGC) business to Capnest Health Care Private Limited. This strategic pivot sees Nectar Lifesciences now focusing on the real estate sector, having acquired Avensis Exports Private Limited as a wholly-owned subsidiary.

Why this matters

The divestment of its operational businesses has resulted in zero revenue from operations for the financial year ended March 31, 2026. This fundamental shift means the company's financial performance is no longer tied to its historical pharmaceutical operations. Investors will need to evaluate the company's potential in the real estate sector.

The backstory

Nectar Lifesciences was primarily a pharmaceutical company. The decision to sell off its core businesses and venture into real estate marks a significant departure from its long-standing operational focus.

What changes now

The company's future earnings will be driven by its real estate ventures. The sale of the pharma business generated a consideration of INR 12,539.86 million, resulting in an exceptional gain of INR 1,633.73 million. The company also completed a share buy-back of 30 million equity shares for INR 810 million.

Risks to watch

The primary risks include the company's ability to successfully establish and generate profits from its new real estate business, the potential delays or failure in the sale of the capsule business, and managing the existing net losses and cash flow until the new business gains traction.

Peer comparison

As Nectar Lifesciences shifts focus to real estate, direct comparison with its former pharmaceutical peers is no longer relevant. Its performance will now be benchmarked against companies operating in the Indian real estate sector.

Context metrics (time-bound)

• Revenue from Operations (FY 2025-26): Nil
• Net Loss After Tax (FY 2025-26): INR 2,928.91 million
• Profit (Loss) Before Tax (Continuing Operations, FY 2025-26): (INR 878.79 million)
• Pharma Business Sale Consideration: INR 12,539.86 million
• Share Buy-back Amount: INR 810 million

What to track next

Investors should closely monitor the progress of the sale of the EHGC business, the company's real estate acquisition and development pipeline, and its financial performance in the upcoming quarters as it navigates its new business model.